Fujian Haixi Pharma shareholders approved external auditor change at EGM

• Fujian Haixi Pharmaceuticals held an extraordinary general meeting on Aug. 4, 2026.
• Shareholders backed a change of external auditor, clearing the way to dismiss Deloitte Touche Tohmatsu.
• The meeting also authorized the appointment of RSM China CPA LLP as auditor for 2026; the change was approved, not yet reported as completed.
• Investors also passed a resolution to appoint an executive director; Wang Xinkun retired at the meeting’s close.
• Chen Tingze joined the board as an executive director, effective from the conclusion of the meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fujian Haixi Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260804-12270900), on August 04, 2026, and is solely responsible for the information contained therein.